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ABSTRACT
Objectives To describe the benefits and limitations 
of using individual and combinations of linked English 
electronic health data to identify incident cancers.
Design and setting Our descriptive study uses linked 
English Clinical Practice Research Datalink primary care; 
cancer registration; hospitalisation and death registration 
data.
Participants and measures We implemented case 
definitions to identify first site- specific cancers at the 
20 most common sites, based on the first ever cancer 
diagnosis recorded in each individual or commonly used 
combination of data sources between 2000 and 2014. 
We calculated positive predictive values and sensitivities 
of each definition, compared with a gold standard 
algorithm that used information from all linked data sets 
to identify first cancers. We described completeness of 
grade and stage information in the cancer registration 
data set.
Results 165 953 gold standard cancers were identified. 
Positive predictive values of all case definitions were 
≥80% and ≥94% for the four most common cancers 
(breast, lung, colorectal and prostate). Sensitivity for 
case definitions that used cancer registration alone or in 
combination was ≥92% for the four most common cancers 
and ≥80% across all cancer sites except bladder cancer 
(65% using cancer registration alone). For case definitions 
using linked primary care, hospitalisation and death 
registration data, sensitivity was ≥89% for the four most 
common cancers, and ≥80% for all cancer sites except 
kidney (69%), oral cavity (76%) and ovarian cancer (78%). 
When primary care or hospitalisation data were used 
alone, sensitivities were generally lower and diagnosis 
dates were delayed. Completeness of staging data in 
cancer registration data was high from 2012 (minimum 
76.0% in 2012 and 86.4% in 2014 for the four most 
common cancers).
Conclusions Ascertainment of incident cancers was 
good when using cancer registration data alone or in 
combination with other data sets, and for the majority 
of cancers when using a combination of primary care, 
hospitalisation and death registration data.
INTRODUCTION
The Clinical Practice Research Datalink 
(CPRD) provides de- identified primary care 
data linked to additional secondary health 
data sources, under a well- governed frame-
work.1 Use of linked data helps researchers 
to answer more epidemiological questions 
and increase study quality through improved 
exposure, outcome and covariate classifica-
tion.2 In the field of cancer epidemiology, 
CPRD primary care data linked to Hospital 
Episode Statistics Admitted Patient Care 
Strengths and limitations of this study
 ► This is the first study to present comprehensive in-
formation on the implications of using different indi-
vidual and combinations of linked electronic health 
data sources in England to identify cases of the 20 
most common incident cancers.
 ► Using a gold standard algorithm that combined all 
available data from multiple sources as a compara-
tor, we were able to estimate both positive predictive 
values and sensitivity values for a range of pragmat-
ic case definitions.
 ► We described similarities and differences in values 
between age groups, sexes and calendar years, the 
impact of choice of source(s) on diagnosis dates and 
mortality rates and completeness of stage and grade 
in cancer registration data.
 ► A key limitation was that our gold standard algorithm 
is not validated and may be affected by differences 
in clinical diagnosis and coding of invasive cancers 
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data (HES APC), Office of National Statistics (ONS) 
mortality and National Cancer Registration and Anal-
ysis Service (NCRAS) cancer registration data are used 
to analyse factors contributing to the risk of cancer and 
the consequences of cancer and its treatment. Use of 
linked data reduces the sample to the common source 
population and data coverage period for each included 
data set, and has cost and logistical implications, which 
are greatest for NCRAS data. Research teams therefore 
commonly choose not to use all available linked data.3 
Cancer epidemiology studies can also be conducted 
using NCRAS and HES APC data provided by National 
Health Service (NHS) Digital and Public Health England 
(PHE), without linkage to CPRD primary care data.4 This 
provides national coverage at the expense of the detailed 
health data that are available in primary care records.
Validation studies assessing concordance between 
CPRD GOLD, HES APC and NCRAS data have estimated 
high positive predictive values (PPVs) for CPRD GOLD 
data and varying proportions of registered cancers that 
are not captured in CPRD GOLD and HES APC.5–8 The 
most up- to- date analysis by Arhi et al included the five 
most common cancers and all papers focussed on concor-
dance between CPRD GOLD only and NCRAS; existing 
evidence therefore does not provide a complete assess-
ment of the benefits and limitations of using different 
combinations of data sources within the context of prac-
tical study designs. National data are available describing 
completeness of data fields within the cancer registry 
data in each collection year9 and over time for all cancers 
combined4; missingness for individual years has been 
associated with age, comorbidities and Clinical Commis-
sioning Groups.10 11
We aim to describe and compare the benefits and limita-
tions of using different combinations of linked CPRD 
primary care data, HES APC, ONS mortality and NCRAS 
cancer registration data, for conducting cancer epide-
miology studies. Our analyses focus on incident cancer 
ascertainment as it is a common and important outcome 
in cancer epidemiology, and it is more difficult to distin-
guish between secondary, recurrent and primary cancers 
at a second site in these data sets. We have compared 
definitions of the 20 most common cancers based on the 
first ever cancer recorded in individual or combinations 
of data sets with a gold standard definition comparing 
information from all four data sets. We also describe the 
availability of stage, grade and treatment variables over 
time in the cancer registration data for the CPRD linked 
cohort. This reflects real- life study design and will help 
researchers to decide which combination of data sources 
to use for future studies.
METHODS
Study design and setting
We completed a concordance study using linked2 English 
CPRD GOLD, HES APC, ONS mortality and NCRAS data. 
CPRD GOLD data were extracted from the January 2017 
monthly release and the 13th update to CPRD’s linked 
data. The study period was from 1 January 2000 to 31 
December 2014, with 31 December 2014 matching the 
end of the NCRAS coverage period.
The CPRD GOLD database includes de- identified 
records from participating general practices in the UK 
who use Vision software.1 General practice staff can 
record cancer diagnoses using Read codes or in free text 
comments boxes, though the latter are not collected 
by CPRD. Diagnoses will typically be entered during/
following a consultation or from written information 
that is returned to the practice from secondary care. 
CPRD GOLD data are linked to HES APC, ONS mortality 
and NCRAS through a trusted third party for English 
practices that have agreed to participate in the linkage 
programme.2 HES APC data are collected by NHS Digital 
to co- ordinate clinical care in England and calculate 
hospital payments.12 Admissions for and related to cancer 
diagnoses are recorded using International Classification 
of Diseases, version 10 (ICD-10) codes. National cancer 
registration data are collected by NCRAS which is part 
of PHE in accordance with the Cancer Outcomes and 
Services Data set13 which has been the national standard 
for reporting of cancer in England since January 2013. 
Data include ICD-10 codes to identify the cancer site and 
more detailed information such as stage and grade. ONS 
mortality data includes dates and causes of deaths regis-
tered in England, recorded using ICD-10 codes.
Participants, exposures and outcomes
Our underlying study population included male and 
female patients registered in CPRD GOLD practices 
who were eligible for linkage to HES APC, NCRAS and 
ONS mortality data and had at least 365 days of follow- up 
between 1 January 1999 and 31 December 2014. Start of 
follow- up was defined as the latest of the current regis-
tration date within the practice and the CPRD estimated 
start of continuous data collection for the practice (up- to- 
standard date). End of follow- up was determined as the 
date the patient left the practice, ONS mortality date of 
death or practice last collection date.
Identification and classification of cancer codes
We used code lists to classify cancer records in each of 
CPRD GOLD, HES APC and ONS mortality data as one of 
the 20 most common sites, other specified cancers, history 
of cancer, secondary cancers, benign tumours, admin-
istrative cancer codes, unspecified and incompletely 
specified cancer codes (https:// doi. org/ 10. 17037/ data. 
00001519). Incompletely specified cancer codes could be 
mapped to >1 cancer site (eg, ICD-10 code C68.9 “Malig-
nant neoplasms of urinary organ unspecified” was consid-
ered consistent with both bladder and kidney cancer). 
For NCRAS, we accessed coded records for the 20 most 
common cancers. We included cancers recorded in the 
clinical or referral file for CPRD GOLD, cancers recorded 
in any diagnosis field for HES APC and the underlying or 
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most immediate cancer cause of death in ONS mortality 
data.
Cancer case definitions based on individual sources and 
combinations of sources
We developed alternative cancer case definitions mirroring 
those commonly used in epidemiology studies, based on 
identifying the first malignant cancer (excluding admin-
istrative codes and benign tumours) recorded in various 
combinations of data sources (NCRAS alone; NCRAS and 
HES APC; all sources; CPRD GOLD, HES APC and ONS 
mortality; CPRD GOLD alone, HES APC alone). Multiple 
malignant cancers recorded on the index date in CPRD 
GOLD or HES APC were reclassified as multiple- site 
cancer and were not considered as individual- site cancer 
records for positive predictive value and sensitivity calcu-
lations; multiple codes recorded in different sources on 
the same date were reclassified as the site identified in 
the NCRAS data if available and as multiple- site cancer 
if not. For each case definition, we only examined the 
first malignant cancer per individual where this occurred 
within the study period and at least 1 year after the start 
of follow- up.
Gold standard cancer case definition
We developed a gold standard algorithm that classi-
fies incident records of the 20 most common cancers 
by comparing the first malignant cancer identified in 
each individual source (figure 1). Cancers recorded in 
NCRAS alone with no contradictions (ie, records for 
first cancers at different sites) were considered true cases 
whereas cancers recorded in HES APC alone or GOLD 
alone required internal confirmation within that source 
in the form of another code for cancer consistent with 
the same site (or with site unspecified) within 6 months 
and no contradictory codes (eg, for cancers at other sites) 
in this period. Where cancer records were present in >1 
data source, we considered a site- specific cancer to be 
a true case (a) if it was recorded as the first cancer in 
NCRAS and the total number of data sources with records 
for cancer at that site was equal to or greater than the 
number of data sources with contradictory records (ie, 
records for first cancers at different sites); or (b) where 
the cancer was not present in NCRAS, if there were more 
data sources in total with records for cancer at that site 
than data sources with contradictory records.
We used NCRAS data to identify stage, grade and treat-
ment where available in the cancer registry only cohort. 
Binary surgery, chemotherapy and radiotherapy variables 
were derived using individual records of treatment from 
the first year after diagnosis.
Statistical analysis
For each cancer site and each individual or combined 
data source, we combined our applied study definitions 
Figure 1 Gold standard algorithm to identify incident site- specific cancers using all data sources. HES, Hospital Episode 
Statistics; NCRAS, National Cancer Registration and Analysis Service; ONS, Office of National Statistics.
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with our gold standard definition to classify each applied 
study definition as a true positive, false positive or false 
negative record.
We used these categories to calculate sensitivity and 
positive predictive value overall and stratified by age cate-
gories (<60, 60 to 79 and 80+), calendar year and sex. 
We calculated differences in diagnosis dates for true posi-
tives by subtracting the gold standard index date from the 
index date for each source and combination of sources.
We used Kaplan- Meier methods to describe mortality 
over time for cancers identified using each definition. 
The ONS mortality death date was used for these analyses.
We used the NCRAS only definition to calculate 
proportions of patients with complete stage and grade 
and recorded cancer treatment modalities over time.
Patient public involvement
Patients and the public were not involved in conceiving, 
designing or conducting this study and will not be 
consulted regarding the dissemination of study results.
RESULTS
Of 14 747 047 research quality patients in the CPRD GOLD 
January 2017 build, 8 893 326 were eligible for linkage to 
HES, ONS mortality and NCRAS data in set 13; 237 were 
excluded due to unknown sex. Of the remainder, 6 791 
074 and had at least 1 year of follow- up between 1 January 
1999 and 31 December 2014 and were included in the 
study population. Using the gold standard algorithm, 165 
953 incident cases of cancer were identified. The number 
of patients identified with each cancer is presented in 
online supplementary appendix table 1. Half (50.0%, 
n=82 899) of these patients were male; 24.4% (40 470) 
aged 0 to 59, 54.1% (89 720) aged 60 to 79 and 21.6% (35 
763) aged 80 or older.
Figure 2 presents PPVs for each case definition, 
comparing the first recorded cancer in each combination 
of data sources with the gold standard algorithm. When 
using NCRAS data alone, 91.0% to 99.5% of cancers were 
confirmed by the algorithm; for 19 out of 20 cancer sites, 
the NCRAS- only case definition gave the highest PPV. 
Case definitions using data sources not including NCRAS 
generally had lower PPVs, ranging from 79.6% to 97.3% 
for individual cancer sites. For the four most common 
cancers (breast, lung, colorectal and prostate), PPVs were 
at least 94% for all case definitions. Minimal differences 
in PPVs were observed between age groups, years and 
sexes (online supplementary appendix figures 1–3).
Figure 3 presents sensitivity values for each case defi-
nition. Sensitivity was generally higher for the case defi-
nitions that included NCRAS data (ranging from 80.9% 
to 98.7% for individual cancer sites except bladder 
cancer identified using NCRAS data alone (64.8%), and 
≥92% for the four most common cancers (breast, lung, 
colorectal and prostate)). Sensitivity was also generally 
high for definitions using a combination of CPRD GOLD, 
HES APC and ONS mortality data (ranging from 69.2% 
to 96.3%, ≥89% for the four most common cancers). 
Sensitivity was lower for case definitions that used CPRD 
GOLD alone (range 31.5% to 89.3% for individual cancer 
sites) or HES APC alone (range 55.9% to 92.6%). Sensi-
tivity values for CPRD GOLD alone and HES APC alone 
increased slightly in younger patients and more recent 
years; no differences were observed between men and 
women (online supplementary appendix figures 4–6). 
Post- hoc analysis suggested that the low sensitivity of 
CPRD GOLD only definitions for kidney cancer (sensi-
tivity 31.5%, n false negatives 2869) was driven by missing 
(n=1136, 39.6%) or incompletely specified urinary organ 
cancer codes (n=1108, 38.6%) in CPRD GOLD rather 
than contradictory information about the first cancer 
record (n=625, 21.8%). These incompletely specified 
codes are less likely to be used for bladder cancers (n=85) 
than kidney cancers (n=1108). Bladder cancers that were 
not recorded in NCRAS data (n=3445) were commonly 
recorded in both HES APC and CPRD GOLD (n=2228, 
64.7%) or in HES APC only with a subsequent unspec-
ified or bladder cancer record in HES APC within 6 
months (n=995, 28.9%).
Table 1 describes the number of days (median IQR 
and 5th/95th percentile) lag between the date of incident 
cancers from the gold standard definition and the date 
of cancer arising from each case definition (ie, the first 
record within the specific combinations of data sources 
used). Case definitions using NCRAS alone and combi-
nations of ≥2 data sources captured cancers close to the 
gold standard date (median lag ≤7 days for all cancer 
sites), whereas median lags were generally longer for the 
case definitions using CPRD GOLD alone and HES APC 
alone.
Figure 4 describes mortality over time following inci-
dent cancer diagnoses ascertained from each case defi-
nition. Minimal differences in mortality were observed 
between cancers identified from different case defini-
tions. Where variability was observed, cancers identified 
using CPRD GOLD only had the lowest mortality rates 
(eg, kidney cancer) and cancers identified using HES 
APC only or NCRAS only had higher mortality rates (eg, 
prostate cancer and bladder cancer, respectively).
Figure 5 describes completeness of grade and stage 
for cancers identified using NCRAS only. Recording of 
grade was highly variable between cancers with gradual 
increases in completeness over time. Completeness of 
staging information was low in earlier calendar years but 
improved substantially from around 2012 especially for 
the four most common cancers (minimum 76.0% in 2012 
and 86.4% in 2014). Post- hoc logistic regression models 
adjusted for year and cancer site indicated that complete-
ness of stage and grade were associated with each other 
and these variables were least complete in patients aged 
>=80; stage data was more complete for higher grade 
tumours whereas grade data was more complete for lower 
stage tumours (online supplementary appendix figure 7).
Online supplementary appendix figure 8 describes 
recording of treatment modalities identified using NCRAS 









pen: first published as 10.1136/bm





5Strongman H, et al. BMJ Open 2020;10:e037719. doi:10.1136/bmjopen-2020-037719
Open access
Figure 2 Positive Predictive Value of cancer diagnoses for each combination of sources when compared with the main gold 
standard algorithm. Percentage of incident cancers defined using the first ever record in each combination of sources confirmed 
by a gold standard algorithm that considers confirmatory and contradictory data from each source. Cancer sites are ordered 
according to corresponding codes from the International Classification of Diseases, version 10 (ICD-10). *Four most common 
cancer sites. CNS, central nervous system; NHL, Non- Hodgkin's lymphoma; CPRD, Clinical Practice Research Datalink; HES 
APC, Hospital Episode Statistics Admitted Patient Care data; NCRAS, National Cancer Registration and Analysis Service; ONS, 
Office of National Statistics.
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Figure 3 Sensitivity of cancer diagnoses for each combination of sources when compared with the main gold standard 
algorithm. Percentage of incident cancers identified using the main gold standard algorithm that considers confirmatory and 
contradictory data from each source that are identified using the first ever record in each combination of sources. Cancer sites 
are ordered according to corresponding codes from the International Classification of Diseases, version 10 (ICD-10). *Four 
most common cancer sites. CNS, central nervous system; NHL, Non- Hodgkin's lymphoma; CPRD, Clinical Practice Research 
Datalink; HES APC, Hospital Episode Statistics Admitted Patient Care data; NCRAS, National Cancer Registration and Analysis 
Service; ONS,Office of National Statistics.
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Figure 4 Mortality following first ever record of cancer in each combination of sources. Cancer sites are ordered according to 
corresponding codes from the International Classification of Diseases, version 10 (ICD-10). *Four most common cancer sites. 
CNS, central nervous system; CPRD, Clinical Practice Research Datalink; HES APC, Hospital Episode Statistics Admitted 
Patient Care data; NCRAS, National Cancer Registration and Analysis Service; NHL, Non- Hodgkin's lymphoma; ONS, Office of 
National Statistics.
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Figure 5 Completeness of grade and stage for cancers identified using NCRAS data only. Cancer sites are ordered according 
to corresponding codes from the International Classification of Diseases, version 10 (ICD-10). *Four most common cancer sites. 
Grading information is not applicable to brain/CNS, sarcoma or haematological cancers and not required by in the national 
data standard (COSD) for prostate cancer. Core staging is not applicable to haematological and gynaecological cancers. Other 
types of staging are recommended by COSD. CNS, central nervous system; COSD, Cancer Outcomes and Services Data set; 
NCRAS, National Cancer Registration and Analysis Service; NHL, Non- Hodgkin's lymphoma.
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only. Missing records may indicate that the patient did 
not receive that treatment modality or that the treatment 
modality was not recorded.
DISCUSSION
Statement of principal findings
We investigated the use of different sources of elec-
tronic health record data to identify incident cancers. 
For all case definitions, using individual or combined 
data sources, a minimum of 80% of incident site- 
specific cancers were confirmed using the gold standard 
algorithm; this rose to 94% of the four most common 
cancers. Use of cancer registration data alone or in any 
combination of data sources captured at least 80% of 
site- specific cancers identified by the gold standard 
algorithm, excepting bladder cancer, and 92% of cases 
for the four most common cancers. Combining CPRD 
GOLD, HES APC and ONS mortality data captured at 
least 80% of site- specific cancers excepting kidney, oral 
cavity and ovarian cancers, and captured >=89% of cases 
for the four most common cancers. Sensitivity was much 
more variable when using primary care or hospital data 
alone, and dropped to 65% when identifying bladder 
cancers using cancer registration data alone. Use of 
primary care or hospital data alone resulted in a small 
lag in identifying cancers of interest, compared with the 
gold standard dates but other case definitions captured 
cancers close to the gold standard date. Finally, while 
we observed minimal changes in PPVs and sensitivi-
ties between 2000 and 2014, completeness of NCRAS 
cancer registration stage and grade data increased 
markedly from 2012 onwards for specific cancer types, 
demonstrating that initiatives to improve data can 
have a profound impact on the quality of the data.4 
Completeness of cancer treatment recording was diffi-
cult to assess due to the absence of a missing category.
Strengths and weaknesses of the study
The main strength of this study is that we have devel-
oped a gold standard algorithm using the entirety of the 
evidence available from CPRD to demonstrate the impact 
of choice of data sets in identifying incident cancers for 
real- life studies. We have also assessed the value of using 
NCRAS cancer registration data to measure stage, grade 
and cancer treatment modalities.
A limitation of the study is that our gold standard 
algorithm is not validated. We feel that we were justi-
fied in pre- weighting NCRAS data as more reliable that 
other data sources as NCRAS is a highly validated data 
set that matches, merges and quality checks data from 
multiple sources.4 We did not consider NCRAS to be 
the outright gold standard as it is plausible that NCRAS 
does not identify all tumours diagnosed and treated 
in primary and secondary care. For most cancer sites, 
our gold standard algorithm identified a small propor-
tion of cancers that are recorded in HES APC, CPRD 
GOLD or ONS mortality data but not in NCRAS. These 
tumours may have been diagnosed and coded as invasive 
in primary or secondary care but not by NCRAS; been 
incorrectly coded in HES APC, CPRD GOLD or ONS 
mortality data; not have been notified to NCRAS (eg, 
tumours treated in private hospitals); or be the result 
of linkage errors between the data sets. The proportion 
of cancers identified in HES APC but not in NCRAS is 
particularly high for bladder cancer. This is likely to be 
the result of difficulties, inconsistencies and changes 
in the pathological definition and coding of cancers 
over time in NCRAS, which are greatest for bladder 
cancer.4 14 This explanation is supported by the higher 
mortality rates that we observed in bladder cancer cases 
identified in NCRAS compared with other data sources. 
To identify incident cancers, we required 12 months 
of research quality follow- up in CPRD GOLD prior to 
inclusion in the study. Previous research has demon-
strated that historic data is generally incorporated 
within the patient record with this time frame.15 The 
identification of first ever cancers will also have been 
affected by different lengths of follow- up data available 
in linked data sources as NCRAS data collection started 
in 1990, HES APC in 1997 and ONS mortality data in 
1998, and by the inclusion of all diagnostic codes in HES 
APC assuming that the first ever primary or secondary 
record identified incident cancer. Reassuringly, PPVs for 
liver and brain cancer were high for all individual and 
combinations of data sets suggesting that these were not 
unduly misclassified as primary incident cancers despite 
being common sites for metastases. Requiring internal 
confirmation within 6 months for cancers recorded in 
CPRD GOLD alone in our GOLD standard definition is 
more likely to discount cancers with poorer prognoses 
and those recorded in the last 6 months of follow- up. 
Our data cut only included NCRAS data for the top 20 
cancers; earlier cancers at other sites will have been 
missed in this study.
It is also important to note that as the gold standard 
algorithm uses data recorded after the first record of the 
cancer site in any source (index date), it cannot be used 
to identify outcomes in applied studies and follow- up of 
cohort studies with cancer as an exposure would need to 
start at least 6 months after diagnosis; our first ever cancer 
record in any source definition would be more appro-
priate for most studies.
Strengths and weaknesses in relation to other studies, 
discussing important differences in results
The most up- to- date study describing concordance 
between linked CPRD GOLD, HES APC and NCRAS 
data sets demonstrated that 2% to 4% of the five 
most common cancers recorded in CPRD GOLD are 
not confirmed in either HES APC or cancer registra-
tion data and 9% to 33% of registered cancers are not 
recorded in CPRD GOLD.8 For cancers recorded in 
both sources, the diagnosis date was a median of 6 to 
16 days later in CPRD GOLD than in the cancer regis-
tration data. Using CPRD GOLD alone to identify these 
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cancers marginally over- represented younger, healthier 
patients and identified 1% to 6% fewer deaths in the first 
5 years after diagnosis. Use of HES APC only identified a 
higher proportion of patients with the correct diagnosis 
date than CPRD GOLD, but over- represented older 
patients and those diagnosed through the emergency 
route. The majority of registered cancers were picked 
up using both CPRD GOLD and HES APC (ranging 
from 91% for lung cancer to 97% for breast cancer). 
Previous research demonstrated similar results with 
substantial differences between cancer types.5 6 Addi-
tionally, a study using data from 2001 to 2007 found that 
using HES data in addition to NCRAS data identified 
an additional 1.9%, 0.4% and 2.0% of surgically treated 
colorectal, lung and breast cancer cases, respectively.16
Our study is consistent with these results and provides 
more complete and practical evidence of the strengths 
and limitations of using individual and combinations of 
linked data sets to identify and characterise the 20 most 
common incident cancers.
We have also demonstrated the added value of using 
cancer registration data to measure stage and grade of 
incident cancers from about 2012 onwards. Levels of data 
completeness of staging information in the CPRD extract 
in 2012 were similar to those reported by the United 
Kingdom and Ireland Association of Cancer Registries 
(UKAICR).9
Meaning of the study: possible explanations and implications 
for clinicians and policymakers
Use of NCRAS cancer registration data maximised the 
proportion of cases confirmed as true positive based 
on all available linked information and captured 
the highest proportion of true positive cases; highly 
complete staging and grading information is available 
from this source from approximately 2012. Case defi-
nitions based on a combination of CPRD GOLD, HES 
APC and ONS mortality data also had acceptable validity 
for the majority of cancer sites including the four most 
common cancers.
These findings should be considered when deciding 
which data sources to include in research studies and 
which sources to use to define cancer exposures, outcomes 
and covariates.
UNANSWERED QUESTIONS AND FUTURE RESEARCH
Further research is required to investigate the validity 
of cancer recorded in CPRD GOLD and HES APC that 
are not recorded in the NCRAS data and to under-
stand differences in cancer data recording with CPRD 
GOLD and CPRD Aurum, CPRD’s recently launched 
primary care database based on records from practices 
that use EMIS software.17 Further investigation would 
be required to confidently identify subtypes of cancer, 
either using codes available in each data set (eg, colon 
and rectal cancer) or additional information available 
in HES APC or NCRAS data. Use of NCRAS’s recently 
launched Systemic Anti- Cancer Therapy (SACT)18 and 
National Radiotherapy Data Sets will also improve ascer-
tainment of therapies for future studies.
CONCLUSION
Completeness and accuracy of recording of cancers in 
English data sources is high particularly when using 
NCRAS cancer registration data alone or in any combi-
nation with other data sources, and for the majority of 
cancers when using a combination of CPRD GOLD, 
HES APC and ONS mortality data. Completeness of 
cancer stage and grade variables in NCRAS was low 
before 2012 but appears to have substantially improved 
for most cancers in more recent calendar periods. It is 
not possible to validate completeness of the available 
treatment data; these should be used with caution. 
This study describes likely levels of misclassification 
for a range of data sources, combinations and cancer 
sites enabling cancer epidemiologists to optimise study 
design and better understand the limitations of their 
research.
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